US Drug Pricing Legislation Efforts Headed Toward Spring Renewal? A Look Ahead
Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.
You may also be interested in...
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
President Trump did not offer any new proposals on drug pricing during an evening featuring campaign theatrics on both sides.
Amid questions about generic industry market dynamics, the user fee renewal could focus on limiting increases in US FDA collections.